We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Read MoreHide Full Article
Key Takeaways
Danaher's Q3 adjusted EPS rose 10.5% year over year to $1.89, topping consensus estimates.
Net sales grew 4.5% to $6.05 billion, with all segments contributing to year-over-year gains.
Operating profit jumped 20.5%, expanding margins to 19.1% from 16.5% in the prior year.
Danaher Corporation’s (DHR - Free Report) third-quarter 2025 adjusted earnings of $1.89 per share beat the Zacks Consensus Estimate of $1.71. The bottom line increased 10.5% year over year.
Danaher reported net sales of $6.05 billion, which beat the consensus estimate of $6.00 billion. The metric increased 4.5% year over year, driven by the impressive performance of all the segments.
DHR’s core sales increased 3% year over year in the quarter. Foreign-currency translations had a positive impact of 1.5%.
DHR’s Segmental Discussion
Revenues from the Life Sciences segment totaled $1.79 billion, up 0.5% year over year. We expected the segment’s revenues to be $1.83 billion. However, core sales decreased 1% year over year. Foreign-currency translations had a positive impact of 1.5%. Operating profit was $222 million compared with $35 million reported in the year-ago quarter.
Revenues from the Diagnostics segment totaled $2.46 billion, up 4% year over year. Our estimate for revenues was $2.37 billion. Core sales increased 3.5% year over year, while foreign currency had a positive impact of 1% on sales. However, acquisitions/divestitures impacted sales by 0.5%. Operating profit was $665 million, up 8.1% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.80 billion, up 9% year over year. Our estimate was $1.80 billion. Core sales increased 6.5% year over year, while foreign-currency translations had a positive impact of 2.5%. Operating profit was $352 million, down 9.7% year over year.
Danaher Corporation Price, Consensus and EPS Surprise
In the third quarter, Danaher’s cost of sales increased 5.5% year over year to $2.53 billion. Gross profit of $3.52 billion increased 3.6% year over year. The gross margin was 58.2% compared with 58.7% in the year-ago quarter.
Selling, general and administrative expenses of $2.00 billion recorded a decrease of 3.3% on a year-over-year basis. Research and development expenses were $378 million, down 1.3% year over year.
Danaher’s operating profit increased 20.5% year over year to $1.15 billion. Operating margin expanded to 19.1% from 16.5% in the year-ago quarter.
DHR’s Balance Sheet and Cash Flow
Exiting the third quarter, DHR had cash and equivalents of $1.53 billion compared with $2.08 billion at 2024-end. Long-term debt was $16.8 billion at the end of the quarter compared with $15.5 billion at the end of December 2024.
Danaher generated net cash of $4.30 billion from operating activities in the first nine months of 2025 compared with $4.67 billion in the previous year’s comparable period. Capital expenditures totaled $785 million in the same period, down 10.4% year over year. Adjusted free cash flow decreased 7.5% year over year to $3.52 billion in the first nine months of 2025.
In the same period, DHR paid out dividends of $652 million, up 13.8% on a year-over-year basis.
Danaher’s Outlook
For the third quarter, Danaher expects adjusted core sales from continuing operations to increase in the low single digits on a year-over-year basis. The company expects adjusted earnings to be $7.70-$7.80 per share.
DHR’s Zacks Rank
The company currently carries a Zacks Rank #4 (Sell).
Grupo Cibest S.A. (CIB - Free Report) currently sports a Zacks Rank of 1.
Grupo Cibest delivered a trailing four-quarter average earnings surprise of 6.5%. In the past 60 days, the Zacks Consensus Estimate for CIB’s 2025 earnings has increased 3.3%.
ITT Inc. (ITT - Free Report) presently carries a Zacks Rank #2 (Buy). It has a trailing four-quarter average earnings surprise of 1.5%.
The Zacks Consensus Estimate for ITT’s 2025 earnings has increased 0.2% in the past 60 days.
Flowserve Corporation (FLS - Free Report) presently carries a Zacks Rank of 2. FLS delivered a trailing four-quarter average earnings surprise of 5.5%.
In the past 60 days, the consensus estimate for Flowserve’s 2025 earnings has remained steady.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Key Takeaways
Danaher Corporation’s (DHR - Free Report) third-quarter 2025 adjusted earnings of $1.89 per share beat the Zacks Consensus Estimate of $1.71. The bottom line increased 10.5% year over year.
Danaher reported net sales of $6.05 billion, which beat the consensus estimate of $6.00 billion. The metric increased 4.5% year over year, driven by the impressive performance of all the segments.
DHR’s core sales increased 3% year over year in the quarter. Foreign-currency translations had a positive impact of 1.5%.
DHR’s Segmental Discussion
Revenues from the Life Sciences segment totaled $1.79 billion, up 0.5% year over year. We expected the segment’s revenues to be $1.83 billion. However, core sales decreased 1% year over year. Foreign-currency translations had a positive impact of 1.5%. Operating profit was $222 million compared with $35 million reported in the year-ago quarter.
Revenues from the Diagnostics segment totaled $2.46 billion, up 4% year over year. Our estimate for revenues was $2.37 billion. Core sales increased 3.5% year over year, while foreign currency had a positive impact of 1% on sales. However, acquisitions/divestitures impacted sales by 0.5%. Operating profit was $665 million, up 8.1% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.80 billion, up 9% year over year. Our estimate was $1.80 billion. Core sales increased 6.5% year over year, while foreign-currency translations had a positive impact of 2.5%. Operating profit was $352 million, down 9.7% year over year.
Danaher Corporation Price, Consensus and EPS Surprise
Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote
Danaher’s Margin Profile
In the third quarter, Danaher’s cost of sales increased 5.5% year over year to $2.53 billion. Gross profit of $3.52 billion increased 3.6% year over year. The gross margin was 58.2% compared with 58.7% in the year-ago quarter.
Selling, general and administrative expenses of $2.00 billion recorded a decrease of 3.3% on a year-over-year basis. Research and development expenses were $378 million, down 1.3% year over year.
Danaher’s operating profit increased 20.5% year over year to $1.15 billion. Operating margin expanded to 19.1% from 16.5% in the year-ago quarter.
DHR’s Balance Sheet and Cash Flow
Exiting the third quarter, DHR had cash and equivalents of $1.53 billion compared with $2.08 billion at 2024-end. Long-term debt was $16.8 billion at the end of the quarter compared with $15.5 billion at the end of December 2024.
Danaher generated net cash of $4.30 billion from operating activities in the first nine months of 2025 compared with $4.67 billion in the previous year’s comparable period. Capital expenditures totaled $785 million in the same period, down 10.4% year over year. Adjusted free cash flow decreased 7.5% year over year to $3.52 billion in the first nine months of 2025.
In the same period, DHR paid out dividends of $652 million, up 13.8% on a year-over-year basis.
Danaher’s Outlook
For the third quarter, Danaher expects adjusted core sales from continuing operations to increase in the low single digits on a year-over-year basis. The company expects adjusted earnings to be $7.70-$7.80 per share.
DHR’s Zacks Rank
The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stocks to Consider
Better-ranked companies are discussed below.
Grupo Cibest S.A. (CIB - Free Report) currently sports a Zacks Rank of 1.
Grupo Cibest delivered a trailing four-quarter average earnings surprise of 6.5%. In the past 60 days, the Zacks Consensus Estimate for CIB’s 2025 earnings has increased 3.3%.
ITT Inc. (ITT - Free Report) presently carries a Zacks Rank #2 (Buy). It has a trailing four-quarter average earnings surprise of 1.5%.
The Zacks Consensus Estimate for ITT’s 2025 earnings has increased 0.2% in the past 60 days.
Flowserve Corporation (FLS - Free Report) presently carries a Zacks Rank of 2. FLS delivered a trailing four-quarter average earnings surprise of 5.5%.
In the past 60 days, the consensus estimate for Flowserve’s 2025 earnings has remained steady.